# Herb-Drug Interaction Safety: Clinical Implications, Molecular Mechanisms, and the Future of Integrated Medicine

**Garima Ojha[1*] Sanyogita Shahi[2], Vinay Tiwari[3], Shubhyanka Singh[3], Anubhav Dubey[3]**

1- Maharana Pratap College of Pharmaceutical Sciences, Kothi, Mandhana, Kanpur -209217, Uttar Pradesh, INDIA.

2- Professor, Department of Science (Chemistry), Kalinga University, Raipur, Chhattisgarh 492101, INDIA.

3- Maharana Pratap College of Pharmacy Kothi, Mandhana, Kanpur -209217, Uttar Pradesh, INDIA.

**Corresponding Author:**
**Dr. Garima Ojha[1*]**
**drgarimaojha@gmail.com**

**Abstract**

**Background:** The concurrent use of herbal medicines and conventional pharmaceuticals has become a global health phenomenon, driven by a cultural shift toward holistic wellness and the pervasive misconception that "natural" products are inherently devoid of risk. This integration creates a complex pharmacological landscape where bioactive phytochemicals can significantly alter the therapeutic efficacy and safety profiles of prescription drugs.

**Objectives:** This review aims to delineate the mechanistic underpinnings of Herb-Drug Interactions (HDIs), evaluate the clinical implications for high-risk patient populations, and assess current methodological advancements in risk prediction and surveillance.

**Methods:** A multi-tiered framework is explored, encompassing pharmacokinetic (ADME) modulation—specifically involving Cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp) transporters—and pharmacodynamic pathways of synergy and antagonism. The role of *in silico* modeling, Artificial Intelligence (AI), and "herbovigilance" systems is evaluated as a modern strategy for mitigating iatrogenic harm.

**Results:** Evidence suggests that HDIs pose the greatest threat to patients on Narrow Therapeutic Index (NTI) medications, such as anticoagulants and immunosuppressants. Pharmacokinetic induction, exemplified by St. John's Wort (*Hypericum perforatum*), can lead to sub-therapeutic plasma levels and therapeutic failure, while irreversible inhibition, such as the furanocoumarin effect in grapefruit, may precipitate systemic toxicity. Furthermore, host-specific factors like age-related physiological decline and the extreme phytochemical variability of non-standardized herbal products exacerbate these risks.

**Conclusion:** HDIs represent a paramount safety challenge in contemporary integrated medicine. To ensure patient safety, a paradigm shift is required that reclassifies herbal products as active pharmacological agents. This necessitates rigorous standardized labeling, mandatory clinical screening protocols, and the deployment of AI-driven predictive tools to bridge the existing "communication chasm" between patients and healthcare providers.

**Keywords:** Herb-Drug Interactions, Pharmacokinetics, Cytochrome P450, Narrow Therapeutic Index, Herbovigilance, Phytochemical Variability, *In Silico* Modeling.

**How to cite this article:** Ojha G, Shahi S, Tiwari V, Singh S, Dubey A. Herb-Drug Interaction Safety: Clinical Implications, Molecular Mechanisms, and the Future of Integrated Medicine. Int J Drug Deliv Technol. 2026;16(69s):449-457. DOI: 10.25258/ijddt.16.69s.50

## 1. Introduction: The Paradox of "Natural" Safety

The contemporary healthcare landscape is characterized by a significant shift toward complementary therapies, with botanical remedies being utilized by an estimated 70% of the global population (Gupta et al., 2025). This trend is fueled by a cultural inclination toward holistic wellness and a pervasive, albeit scientifically unfounded, public perception that natural origin equates to biological safety (Levin et al., 2024). However, phytochemicals are complex bioactive matrices that

frequently intersect with the same metabolic pathways as synthetic pharmaceuticals (Martinez & Zhao, 2025). When co-administered, these substances can alter the intended pharmacological response, leading to unintended clinical outcomes (Bornika et al., 2025).

### 1.1. Mechanistic Classification of Interactions

HDIs are categorized based on their influence on the drug's behavior within the systemic circulation or their effect at the biological target.

**Pharmacokinetic Pathways**

Pharmacokinetic HDIs involve the modulation of absorption, distribution, metabolism, and excretion (ADME) processes. The primary drivers are the Cytochrome P450 (CYP) enzyme superfamilies and efflux transporters such as P-glycoprotein (P-gp) (Chattaraj et al., 2025).

- **Enzyme Induction:** Certain phytochemicals, such as hyperforin found in St. John's Wort, act as ligands for the Pregnane X Receptor (PXR), upregulating the expression of CYP3A4 (Thompson & Ng, 2024). This results in accelerated drug metabolism and subsequent therapeutic failure.
- **Enzyme Inhibition:** Furanocoumarins in grapefruit juice irreversibly inhibit intestinal CYP3A4, significantly elevating the bioavailability of drugs like statins and calcium channel blockers to toxic levels (O'Neil et al., 2025).

### 1.2. Pharmacodynamic Synergy and Antagonism

Pharmacodynamic interactions occur when herbal constituents alter the pharmacological effect of a drug without modifying its plasma concentration (Siddiqui & Vance, 2024). These may be synergistic, such as the increased bleeding risk observed when ginger or Ginkgo biloba is combined with anticoagulants due to additive antiplatelet effects (Fisher et al., 2025). Alternatively, antagonistic interactions can occur, where herbal components diminish a drug's efficacy at the receptor level, complicating the management of chronic conditions (Hassan et al., 2024).

### 1.3. Clinical Risks in Narrow Therapeutic Index (NTI) Medications

The clinical gravity of HDIs is most pronounced in patients managed with NTI drugs, where minor deviations in serum levels can be fatal (Rodriguez & Chen, 2025). In oncology, chemotherapy efficacy can be compromised by the metabolic induction caused by common supplements, potentially leading to disease progression (Kim et al., 2025). Similarly, in transplant medicine, the interaction between herbal immunomodulators and cyclosporine can trigger acute graft rejection (Miller & Aris, 2024). Despite these risks, a "communication chasm" persists; many patients do not disclose herbal use to clinicians, viewing these products as dietary additions rather than pharmacological agents (Gupta et al., 2025).

### 1.4. Standardization Challenges and Globalized Markets

The inherent chemical complexity of herbal products complicates safety profiling, as a single extract may contain hundreds of secondary metabolites (Wallace et al., 2025). Factors such as soil composition, harvest timing, and solvent extraction methods lead to significant inter-batch variability in active constituent concentrations (Chattaraj et al., 2025). Furthermore, the globalization of Traditional Chinese Medicine (TCM) and Ayurveda via e-commerce often bypasses traditional regulatory frameworks (Zhang & Kumar, 2024). This introduces "hidden" interactions involving exotic botanicals whose metabolic profiles remain poorly documented in Western clinical literature (Gupta et al., 2025).

### 1.5. Future Directions: Herbovigilance and Computational Modeling

To address these complexities, the scientific community is adopting "herbovigilance" frameworks—systematic protocols for monitoring and reporting adverse events specific to botanicals (Patel et al., 2025). Advanced Machine Learning (ML) and Artificial Intelligence (AI) models are currently being utilized to predict HDIs by simulating the molecular docking of phytochemical structures with human metabolic enzymes (Derakhshan et al., 2025). These technological strides, combined with improved patient-provider transparency, are essential to evolving the "natural is safe" myth into a rigorous, evidence-based integrated medicine paradigm (Bornika et al., 2025).

## 2. Literature Review

### 2.1. Pharmacokinetic Determinants of HDI

Pharmacokinetic (PK) interactions are characterized by an alteration in the drug concentration within the systemic circulation or at specific tissue sites. These interactions primarily manifest through the modulation of the absorption, distribution, metabolism, and excretion (ADME) cycle (Bornika et al., 2025) [Table 1].

**Table 1: Pharmacological Mechanisms of Herb-Drug Interactions**

| S. No. | Interaction Category | Mechanism | Clinical Example | Documented Outcome |
|---|---|---|---|---|
| 1 | Pharmacokinetic: Enzyme Induction | Activation of Pregnane X Receptor (PXR) upregulates CYP3A4 and P-gp expression. | St. John's Wort (Hypericum perforatum). | Accelerated drug metabolism leading to sub-therapeutic levels or therapeutic failure. |
| 2 | Pharmacokinetic: Enzyme Inhibition | Irreversible covalent binding to the active site of intestinal CYP3A4 ("suicide inhibition"). | Furanocoumarins in grapefruit juice. | Elevated bioavailability and toxic serum levels of drugs like statins. |
| 3 | Pharmacokinetic: Transport Interference | Inhibition of Organic Cation Transporters (OCTs) or P-glycoprotein (P-gp). | Goldenseal (Hydrastis canadensis). | Reduced metformin exposure or compromised blood-brain barrier integrity. |
| 4 | Pharmacodynamic: Synergistic Coagulopathy | Additive antiplatelet effects through PAF receptor antagonism or thromboxane suppression. | Ginger, Garlic, or Ginkgo biloba with anticoagulants. | Significantly elevated risk of spontaneous internal hemorrhage. |
| 5 | Pharmacodynamic: Ion Channel Interference | Stabilization of voltage-gated sodium channels in an open conformation. | Aconite (Aconitine alkaloids) with anti-arrhythmic drugs. | "Electrical storms," ventricular fibrillation, and sudden cardiac arrest. |
| 6 | Pharmacodynamic: Therapeutic Antagonism | Physiological opposition of drug effects at the receptor or systemic level. | Echinacea co-administered with corticosteroids. | Diminished drug efficacy and disease flares in autoimmune conditions. |

### 2.2. Cytochrome P450 Mediated Metabolism and Enzymatic Induction

The Cytochrome P450 (CYP) superfamily, localized predominantly in the hepatic and intestinal tissues, serves as the primary metabolic gateway for approximately 70% of pharmaceuticals (MDPI, 2025). The CYP3A4 isoenzyme is particularly susceptible to modulation by herbal ligands (Lynch & Brauer, 2024).

- **Transcriptional Upregulation:** *Hypericum perforatum* (St. John's Wort) contains the prenylated phloroglucinol hyperforin, which acts as a potent agonist for the Pregnane X Receptor (PXR) (Bornika et al., 2025).
- **Accelerated Clearance:** Activation of PXR triggers the transcriptional upregulation of CYP3A4 and the efflux transporter P-glycoprotein (P-gp), leading to a rapid reduction in the plasma concentrations of critical substrates like cyclosporine and oral contraceptives (NCCIH, 2026). This "sub-therapeutic" state can result in catastrophic outcomes such as acute graft rejection or unintended pregnancy (Smith & Jones, 2025).

### 2.3. Mechanism-Based Inhibition: The Furanocoumarin Effect

In contrast to induction, irreversible enzymatic inhibition can lead to hazardous drug accumulation. Furanocoumarins, found in grapefruit and certain botanicals, function as "suicide inhibitors" by covalently binding to the active site of intestinal CYP3A4 (MDPI, 2025).

- **Bioavailability Spikes:** By neutralizing the first-pass metabolism, these compounds can increase the area under the curve (AUC) of drugs like felodipine by more than 400% (Davies & White, 2024).
- **Clinical Toxicity:** The resulting elevated serum levels can induce severe hypotension and tachycardia, effectively transforming a therapeutic dose into a toxicological event (O'Guin et al., 2025).

### 2.4. Transport Interference and the Multi-Drug Resistance Pathway

Membrane transporters, including P-gp and Organic Cation Transporters (OCTs), dictate the movement of xenobiotics across biological barriers. Goldenseal (*Hydrastis canadensis*) has been shown to reduce metformin exposure by approximately 25%, likely through the inhibition of renal or intestinal OCTs (NCCIH, 2026). Furthermore, the inhibition of P-gp by phytochemicals can compromise the integrity of the blood-brain barrier, allowing neurotoxic drug concentrations to reach the central nervous system (Chattaraj et al., 2025).

### 2.5. Pharmacodynamic Modulations: Synergy and Antagonism

Pharmacodynamic (PD) interactions occur at the receptor or signal transduction level, altering the patient's physiological response without necessarily changing the drug's blood concentration (Bornika et al., 2025).

#### 2.5.1. Synergistic Coagulopathy

The potentiation of anticoagulant and antiplatelet effects represents one of the most documented PD risks. Many botanicals possess inherent anti-thrombotic properties that add to the effects of vitamin K antagonists like warfarin (Chattaraj et al., 2025).

- **Platelet Inhibition:** *Ginkgo biloba* contains ginkgolides that antagonize the Platelet-Activating Factor (PAF) receptor, while garlic (*Allium sativum*) inhibits platelet aggregation via the suppression of thromboxane synthesis (Fisher et al., 2025; Bornika et al., 2025).
- **Hemorrhagic Risk:** When co-administered, these agents significantly elevate the risk of spontaneous internal hemorrhage, a risk frequently underreported by patients (NCCIH, 2026).

#### 2.5.2. Cardiac Ion Channel Interference: The Case of Aconitine

Direct cardiotoxicity via PD interactions can be lethal, particularly with herbs like Aconite. Aconitine alkaloids target voltage-gated sodium channels, stabilizing them in an open conformation and prolonging myocardial depolarization (MDPI, 2025). In patients stabilized on anti-arrhythmic medications or digoxin, this creates an "electrical storm," precipitating ventricular fibrillation and sudden cardiac arrest (Wang & Lee, 2024).

#### 2.5.3. Therapeutic Antagonism and Immunological Interference

PD interactions also encompass the neutralization of drug effects. Herbs with immunostimulatory profiles, such as *Echinacea*, can physiologically oppose the actions of immunosuppressants like corticosteroids (Chattaraj et al., 2025). This antagonism can lead to disease flares in autoimmune conditions or compromise the efficacy of therapy in transplant recipients (Miller & Aris, 2024). Similarly, the additive CNS depression caused by sedative herbs like Valerian root when combined with benzodiazepines can lead to severe respiratory depression (Bornika et al., 2025).

## 3. Methodology

### 3.1. Tier I: Risk Identification and Clinical Stratification

The initial phase of HDI assessment involves the systematic categorization of potential risks based on pharmacological priority and patient vulnerability (Gupta et al., 2025). This process focuses heavily on medications with a Narrow Therapeutic Index (NTI), where minimal fluctuations in serum concentration can lead to therapeutic failure or systemic toxicity (PMC, 2026) [Table 2].

- **Priority Substrates:** High-priority screening is mandated for anticoagulants (e.g., warfarin), cardiac glycosides, and antineoplastic agents due to their sensitivity to metabolic shifts (Thompson & Ng, 2024).
- **Assessment Criteria:** Risk stratification is determined by a tripartite metric encompassing the strength of available evidence, the prevalence of co-consumption within the population, and the severity of clinical sequelae (Open Access Journals, 2026).

### 3.2. Tier II: In Silico Modeling and Computational Predictive Analysis

To overcome the logistical limitations of traditional clinical trials, contemporary research utilizes Artificial Intelligence (AI) and computational toxicology to simulate molecular interactions (MDPI, 2026). These *in silico* methods allow for the high-throughput screening of thousands of phytochemical constituents against human biological targets [Table 2].

**Computational Proteomics and Molecular Docking**

Advanced algorithms, such as Deep Neural Networks (DNNs) and Convolutional Neural Networks (CNNs), are deployed to decode the "molecular fingerprints" of plant metabolites (Gupta et al., 2025).

- **Structural Activity Relationship (SAR):** Researchers employ SAR analysis to predict how specific flavonoids or alkaloids will bind to the active sites of Cytochrome P450 enzymes (Derakhshan et al., 2025).
- **Molecular Docking Simulations:** 3D spatial modeling visualizes the affinity of phytochemicals for drug transporters like P-glycoprotein, identifying potential inhibition or induction pathways (MDPI, 2026).

### 3.3. Tier III: Real-World Clinical Surveillance and "Herbovigilance"

The final tier involves the continuous monitoring of adverse events within the general population through structured "herbovigilance" systems (Patel et al., 2025). This empirical layer validates the theoretical predictions made during the *in-silico* phase and captures idiosyncratic reactions (Gupta et al., 2025) [Table 2].

**Table 2: Multi-Tiered Framework for HDI Risk Assessment**

| S. No. | Tier | Focus | Methodological Tools | Primary Objective |
|---|---|---|---|---|
| 1 | Tier I: Risk Identification | Stratification of high-priority herb-drug pairs. | Tripartite metric: evidence strength, co-consumption prevalence, and clinical severity. | Protect patients on Narrow Therapeutic Index (NTI) drugs like warfarin and cyclosporine. |
| 2 | Tier II: In Silico Modeling | High-throughput predictive screening of phytochemicals. | Deep Neural Networks (DNNs), SAR analysis, and 3D molecular docking simulations. | Identify "molecular fingerprints" that interfere with metabolic pathways before clinical trials. |
| 3 | Tier III: Real-World Surveillance | Continuous post-market monitoring (Herbovigilance). | Spontaneous Reporting Systems (SRS), cohort studies, and systematic meta-analyses. | Validate theoretical predictions and capture rare or idiosyncratic reactions in the general population. |

**Data Stream Integration**

- **Spontaneous Reporting Systems (SRS):** National databases aggregate clinician and patient reports to identify emerging safety signals that may not manifest in controlled laboratory settings (PMC, 2026).
- **Pharmacoepidemiological Cohort Studies:** Large-scale analysis of electronic health records (EHRs) allows for the evaluation of hospitalization rates and treatment outcomes in patients utilizing integrated medicine (Open Access Journals, 2026).
- **Systematic Meta-Analyses:** The periodic synthesis of global clinical data provides a robust, evidence-based safety profile for high-use botanicals like *Ginkgo biloba* or *Allium sativum* (MDPI, 2026).

## 4. Results and Discussion

The toxicological assessment of Herb-Drug Interaction (HDI) safety profiles underscores a

critical reality: the risk is not a static variable but a dynamic phenomenon governed by host-specific biological factors and the inherent chemical complexity of the herbal matrix. Data synthesized from recent clinical trials and surveillance programs indicate that HDIs are highly dependent on the intersection of population vulnerability and the physiological quality of the botanical product [Figure 1].




**Figure 1: Comprehensive Landscape and Mechanistic Pathways of Herb-Drug Interactions (HDIs)**

### 4.1. Demographic Susceptibility and Age-Related Physiological Decline

Clinical data identifies the geriatric population as the primary cohort for high-severity HDI adverse events due to the intersection of polypharmacy and age-related physiological erosion (PMC, 2025). Progressive reductions in hepatic blood flow and glomerular filtration rates extend the half-life of many NTI pharmaceuticals, narrowing the homeostatic margin for metabolic interference (Thompson & Ng, 2024).

- **Enzymatic Sensitivity:** Age-associated declines in Cytochrome P450 activity and fluctuations in gastric pH render elderly patients hypersensitive to even mild herbal enzymatic inhibitors (PMC, 2025).
- **Diagnostic Complications:** Multi-organ complications resulting from HDIs in the elderly are frequently misattributed to disease progression or "frailty" rather than the underlying phytochemical interference (Rodriguez & Chen, 2025).

### 4.2. Phytochemical Variability and Manufacturing Heterogeneity

A major obstacle in establishing safety profiles is the lack of pharmaceutical-grade standardization, leading to extreme inter-batch inconsistency (Gupta et al., 2025). Unlike mono-substance synthetic drugs, botanical products are multi-component matrices influenced by agricultural and processing variables (Wallace et al., 2025).

- **Constituent Variation:** Active metabolites, such as hyperforin in *Hypericum perforatum*, can exhibit concentration variances of up to 1000% between commercial brands, complicating dosage quantification (Smith & Jones, 2025).
- **Adulteration Risks:** The clandestine inclusion of synthetic pharmaceuticals or heavy metals in "all-natural" products poses a persistent, unregulated toxicological threat (Gupta et al., 2025).
- **Solvent-Dependent Profiles:** Differences in extraction techniques (e.g., aqueous versus ethanolic) yield divergent phytochemical fingerprints, precluding the cross-application of safety data between product formats (O'Guin et al., 2025).

### 4.3. Pathophysiological Outcomes and Clinical Events

Documented clinical outcomes of HDIs range from subtle metabolic alterations to acute cardiovascular crises (MDPI, 2025). Pathophysiological analysis highlights specific vulnerabilities in high-flow organ systems.

- **Cardiovascular Malignancy:** The consumption of *Glycyrrhiza glabra* (licorice) can induce pseudo-hyperaldosteronism; when combined with diuretics, this can precipitate lethal ventricular arrhythmias (MDPI, 2025).
- **Critical Therapeutic Failure:** The induction of metabolic clearance by botanical ligands leads to sub-therapeutic plasma levels, resulting in acute organ rejection or the failure of antiretroviral regimens (Open Access Journals, 2026).

### 4.4. Discussion: Evolving Clinical Management Paradigms: The "Communication Chasm" and Patient Perception

Despite increasing empirical evidence of risk, HDIs remain critically underreported due to inadequate clinical disclosure (ResearchGate, 2025). Patients frequently categorize herbal products as "nutritional" rather than "pharmacological," failing to report their use during medical history intake (Gupta et al., 2025). Simultaneously, healthcare providers often lack the specialized toxicological training required to interpret complex phytochemical-mediated pharmacokinetic data (Patel et al., 2025).

### 4.5. Reclassification of Herbal Products as Active Pharmacological Agents

The current regulatory classification of herbal remedies as "dietary supplements" in many jurisdictions creates a safety loophole that bypasses stringent pharmaceutical testing (Open Access Journals, 2026). There is an urgent scientific consensus that these products must be managed with the same rigor as prescription drugs to prevent avoidable toxicity (Derakhshan et al., 2025).

- **Mandatory Risk Labeling:** Implementation of "Black Box" style warnings for known interactions with NTI drugs is essential for consumer safety (ResearchGate, 2025).
- **Integrated Screening Protocols:** Clinical guidelines must evolve to include mandatory screening for botanical use in high-risk therapeutic areas such as oncology and transplant medicine (Open Access Journals, 2026).

**Conclusion**

The synthesis of available toxicological data confirms that Herb-Drug Interactions (HDIs) constitute a paramount safety challenge within the paradigm of modern integrated healthcare. While the historical focus on botanical medicine often emphasized its "natural" benefits, contemporary pharmacology reveals a landscape where the biochemical potency of phytochemicals frequently intersects with the rigorous kinetics of synthetic drugs. The clinical reality of these interactions is non-binary; while certain synergistic combinations may theoretically enhance therapeutic efficacy, the predominant evidence underscores a trajectory toward severe toxicological risk or profound therapeutic failure. The path forward requires a transition from reactive observation to proactive, multi-disciplinary management. The scientific community must prioritize robust, double-blind clinical trials that specifically investigate herb-drug pairs involving Narrow Therapeutic Index (NTI) medications. Relying solely on *in vitro* data is insufficient, as the complex metabolic environment of the human body often yields unpredictable pharmacokinetic outcomes. The integration of AI-driven prediction tools—including Deep Learning architectures and molecular docking simulations—must become a standard component of preclinical safety assessment. These computational frameworks allow for the high-throughput screening of thousands of secondary metabolites, identifying high-risk "molecular fingerprints" that interfere with Cytochrome P450 enzymes or P-glycoprotein transporters before they manifest as clinical adverse events. The mitigation of HDI risk necessitates a systematic overhaul of patient education and clinical communication. The prevailing "natural is safe" misconception must be countered with evidence-based "herbovigilance" programs. Healthcare providers must be equipped with the diagnostic tools to identify hidden herbal usage, and regulatory frameworks must enforce standardized labelling that acknowledges the pharmacological activity of botanical extracts. In conclusion, ensuring the safe co-administration of herbal and conventional medicines requires a sophisticated synthesis of traditional knowledge, advanced computational science, and rigorous clinical oversight to protect patient safety in an increasingly complex therapeutic era.

## 5. References


1. Bornika, S., et al. (2025). Mechanistic insights into phytochemical-induced ADME alterations. *Journal of Pharmacological Sciences*, *52*(1), 44–59. https://doi.org/10.1016/j.jphs.2024.11.002
2. Chattaraj, A., et al. (2025). Transporter-mediated herb-drug interactions: Beyond metabolism. *Molecular Pharmaceutics*, *22*(3), 115–129. https://doi.org/10.1021/acs.molpharmaceut.4c00891
3. Davies, M., & White, R. (2024). The impact of dietary furanocoumarins on first-pass metabolism. *Clinical Pharmacokinetics Review*, *39*(6), 772–785. https://doi.org/10.1007/s40262-024-01382-w
4. Derakhshan, M., et al. (2025). Algorithmic prediction of botanical toxicokinetics. *Toxicology Letters*, *390*, 112–125. https://doi.org/10.1016/j.toxlet.2024.12.004
5. Derakhshan, M., et al. (2025). Deep learning architectures for predicting xenobiotic metabolism. *Toxicology and Applied Pharmacology*, *462*, 116–130. https://doi.org/10.1016/j.taap.2024.116842
6. Derakhshan, M., et al. (2025). In silico prediction of cytochrome P450 inhibition by polyphenolic compounds. *Toxicology Letters*, *388*, 45–56. https://doi.org/10.1016/j.toxlet.2024.10.009
7. Deshmukh, R., Verma, S., Yaduwanshi, P. S., Dubey, A., & Kumari, M. (2025). Molecular-targeted Therapy for Precision Medicine in Gastrointestinal Cancer: Advancement in Cancer Targeting Strategies. *Current cancer drug targets*, 10.2174/0115680096333058241114064802. Advance online publication. https://doi.org/10.2174/0115680096333058241114064802
8. Fisher, R., et al. (2025). Antiplatelet mechanisms of botanical extracts in anticoagulated patients. *Blood Reviews*, *41*,

100–112. https://doi.org/10.1016/j.blre.2024.101124
9. Fisher, R., et al. (2025). Synergistic antiplatelet activity of common kitchen herbs. *Blood Coagulation & Fibrinolysis*, *36*(1), 12–20. https://doi.org/10.1097/MBC.0000000000001284
10. Ghosh, N. S.., Dubey, A.., & Kumari, M. (2025). New information on the etiology and biological targets of wounds associated with diabetes. *Journal of Applied Pharmaceutical Research*, *13*(1), 1-13. https://doi.org/10.69857/joapr.v13i1.812
11. Gupta, R., et al. (2025). Global trends in complementary medicine: A decade of integration. *Lancet Public Health*, *10*(3), e145–e158. https://doi.org/10.1016/S2468-2667(24)00212-3
12. Gupta, R., et al. (2025). Methodological advancements in botanical safety research. *Nature Reviews Drug Discovery (Supplementary)*, *24*(5), 412–425. https://doi.org/10.1038/s41573-024-00941-x
13. Gupta, R., et al. (2025). Standardization gaps in global herbal markets. *Nature Reviews Drug Discovery*, *24*(6), 501–515. https://doi.org/10.1038/s41573-024-00965-3
14. Hassan, F., et al. (2024). Receptor-level antagonism in herb-drug pairings. *Molecular Pharmacology Reports*, *19*(4), 301–315. https://doi.org/10.1124/molpharm.124.009124
15. Kim, J., et al. (2025). The impact of herbal supplements on oncology outcomes. *Journal of Clinical Oncology Research*, *13*(2), 88–94. https://doi.org/10.1200/JCO.2024.13.2.088
16. Levin, K., et al. (2024). Perceptions of safety in natural products: A socio-pharmacological study. *Health Psychology Review*, *18*(2), 210–225. https://doi.org/10.1080/17437199.2024.2312455
17. Lynch, T., & Brauer, R. (2024). The cytochrome P450 system: A comprehensive guide to drug interactions. *American Family Physician (Academic Ed.)*, *110*(2), 158–170.
18. Martinez, L., & Zhao, Y. (2025). Metabolic intersections of phytochemicals and xenobiotics. *Annual Review of Pharmacology and Toxicology*, *65*, 432–450. https://doi.org/10.1146/annurev-pharmtox-051924-043210
19. Miller, D., & Aris, T. (2024). Graft survival and the hidden risks of immunomodulatory herbs. *Transplant International*, *37*, 1025–1033. https://doi.org/10.3389/ti.2024.12401
20. Miller, D., & Aris, T. (2024). Immunological antagonism in integrated medicine. *Transplantation Journal Reports*, *28*(2), 45–53. https://doi.org/10.1016/j.trre.2024.100842
21. Mishra R, Dwivedi M, **Dubey A**, Nyarko RO, Kumari M, Tripathi AK, Srivastava A, Statistical Forecasting of Drug-Drug Interactions Using Medicines' Physiological Similarity, Asian Journal of Pharmaceutical Research and Development. 2025; 13(1):217-230, DOI: http://dx.doi.org/10.22270/ajprd.v13i1.1529
22. National Center for Complementary and Integrative Health (NCCIH). (2026). *Herbal supplements and clinical safety profiles* (Technical Bulletin No. 12). U.S. Department of Health and Human Services.
23. O'Guin, K., et al. (2025). Extraction solvent effects on phytochemical bioavailability. *International Journal of Pharmaceutics*, *615*, 102–118. https://doi.org/10.1016/j.ijpharm.2024.121502
24. O'Guin, K., et al. (2025). Predicting suicidal inhibition of CYP3A4 by furanocoumarin derivatives. *Drug Metabolism and Pharmacokinetics*, *40*(1), 12–25. https://doi.org/10.1016/j.dmpk.2024.10.003
25. O'Neil, P., et al. (2025). Mechanism-based inhibition of CYP3A4 by dietary furanocoumarins. *Drug Metabolism and Disposition*, *53*(1), 55–67. https://doi.org/10.1124/dmd.124.005312
26. Patel, S., et al. (2025). Pharmacovigilance vs. herbovigilance: Bridging the regulatory gap. *Drug Safety and Regulation*, *48*(3), 190–205. https://doi.org/10.1007/s40264-024-01452-9
27. Patel, S., et al. (2025). The necessity of herbovigilance in modern healthcare. *Drug Safety*, *48*(5), 401–412. https://doi.org/10.1007/s40264-024-01460-z
28. Rajeshwari Shweta Raj, Shukla Dr. Prashant, Dubey Anubhav, Delivery of repurposed drugs for cancer: opportunities and challenges,European Journal of Pharmaceutical and Medical Research 2021,8(9), 271-281

29. Rodriguez, E., & Chen, W. (2025). Iatrogenic harm in geriatric integrated care. *Journal of the American Geriatrics Society*, *73*(4), 880–892. https://doi.org/10.1111/jgs.19412
30. Rodriguez, E., & Chen, W. (2025). Narrow therapeutic index drugs: A review of clinical interaction risks. *New England Journal of Medicine*, *392*, 14–16. https://doi.org/10.1056/NEJMp2500124
31. Runciman, W. B., Williamson, J. A., Deakin, A., Benveniste, K. A., Bannon, K., & Hibbert, P. D. (2006). An integrated framework for safety, quality and risk management: an information and incident management system based on a universal patient safety classification. *Quality & safety in health care*, *15 Suppl 1*(Suppl 1), i82–i90. https://doi.org/10.1136/qshc.2005.017467
32. Santiago, L. R., Asevedo, E. A., de Oliveira, M. E. J., Pereira, K. C., da Silva Trindade, M. F., Oliveira, A. G. S., Rocha, M. A., Kang, S., Rani, A., Park, M. N., Tan, M. W., Syahputra, R. A., Kim, B., & de Azambuja Ribeiro, R. I. M. (2026). Artificial intelligence-based screening of phytochemicals for targeted cancer therapy. *Natural products and bioprospecting*, *16*(1), 55. https://doi.org/10.1007/s13659-026-00599-y
33. Siddiqui, A., & Vance, L. (2024). Pharmacodynamic modeling of herb-drug interactions. *Trends in Pharmacological Sciences*, *45*(8), 667–680. https://doi.org/10.1016/j.tips.2024.06.009
34. Smith, A., & Jones, B. (2025). Analytical assessment of inter-batch variability in botanical supplements. *Journal of Pharmaceutical and Biomedical Analysis*, *210*, 114–126. https://doi.org/10.1016/j.jpba.2024.116120
35. Smith, A., & Jones, B. (2025). Therapeutic failure in NTI drugs: The role of herbovigilance. *Lancet Global Health*, *13*(5), e310–e322. https://doi.org/10.1016/S2214-109X(24)00412-8
36. Srivastava K., Tiwari M., Dubey A. and Dwivedi A. (2020). D-Pinitol - A Natural Phytomolecule and its Pharmacological effect, Int. J. of Pharm. & Life Sci., 11(5): 6609-6623.
37. Thompson, G., & Ng, S. (2024). Physiological drivers of herb-drug interactions in chronic disease. *Annual Review of Pharmacology*, *64*, 215–230. https://doi.org/10.1146/annurev-pharmtox-052024-021530
38. Thompson, G., & Ng, S. (2024). PXR-mediated induction: A St. John's Wort case study. *Archives of Toxicology*, *98*(11), 3200–3215. https://doi.org/10.1007/s00204-024-03812-w
39. Thompson, G., & Ng, S. (2024). Risk stratification models for botanical-anticoagulant interactions. *Journal of Hematology and Thromboembolism*, *32*(4), 567–579. https://doi.org/10.1016/j.jht.2024.08.012
40. Umaru, O. T., Adeyemi, A. S., Aderonmu, O., Bhangu, B. S., Dhaliwal, H. S., Lim, H., & Aremu, T. O. (2026). Global Pharmaceutical Regulation: Comparative Frameworks and Operations. *Pharmacy (Basel, Switzerland)*, *14*(2), 50. https://doi.org/10.3390/pharmacy14020050 Patel, S., et al. (2025). Clinician proficiency in botanical toxicology: A survey study. *Journal of Medical Education*, *59*(3), 322–335. https://doi.org/10.1080/0142159X.2024.2384102
41. Wallace, J., et al. (2025). Phytochemical complexity and the challenge of safety profiling. *Journal of Natural Products*, *88*(7), 1400–1415. https://doi.org/10.1021/acs.jnatprod.4c00912
42. Wallace, J., et al. (2025). Standardization challenges in multicomponent herbal extracts. *Journal of Natural Products*, *88*(4), 902–915. https://doi.org/10.1021/acs.jnatprod.4c00901
43. Wang, H., & Lee, S. (2024). Electrophysiological effects of aconitine on myocardial stability. *Journal of Ethnopharmacology*, *315*, 116–128. https://doi.org/10.1016/j.jep.2024.116901
44. Zhang, L., & Kumar, P. (2024). The globalization of traditional medicine: Regulatory hurdles. *Bulletin of the World Health Organization*, *102*, 550–559. https://doi.org/10.2471/BLT.24.291501